Arrowhead to Present at Upcoming Conferences

齐欢畅2

Arrowhead to Present at Upcoming Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.
The Liver Meeting 2015®, 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) - San Francisco, November 13-17, 2015
November 15, 3:15 p.m. PST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver an oral presentation titled, "Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg"November 16, 8:00 a.m. - 5:30 p.m. PST - Man-Fung Yuen, M.D., Ph.D., chair of gastroenterology and hepatology, The University of Hong Kong, and deputy chief of service, Queen Mary Hospital department of medicine, Hong Kong, will deliver a late-breaking poster presentation titled, "ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B"

November 16, 6:30 p.m. PST - Arrowhead management will host an Analyst and Investor Reception to discuss ARC-520 and key data being presented at the conference

November 17, 8:00 a.m. - 12:00 p.m. PST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver a poster presentation titled, "Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens"Jefferies Autumn 2015 Global Healthcare Conference - London, UK, November 18-19, 2015
November 19, 2:40 p.m. GMT - Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overviewPiper Jaffray 27th Annual Healthcare Conference - New York, December 1-2, 2015
December 2, 3:00 p.m. EST - Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper JaffrayHEP DART 2015 - Wailea, Hawaii, December 6-10, 2015
December 2, 6:40 p.m. HST - Bruce Given, M.D., Arrowhead chief operating officer, will deliver an oral presentation titled, "New insights on HBV biology from the ARC-520 development program"December 8, 4:00 - 5:30 p.m. HST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver a poster presentation titled, "Sustained reduction in HBsAg, HBV DNA and HBeAg seroconversion in a chronically HBV-infected chimpanzee treated with nucleoside analog/ARC-520 combination therapy"

ivanich

深入，持久，快速，最好来个价廉！就完美了！我怎么会感觉hbv已经是箭头的囊中之物了！

阳光醉人

箭头将出席即将举行的会议
帕萨迪纳，加利福尼亚州——（美国商业资讯）——箭头研究公司（纳斯达克股票代码：ARWR），一家生物制药公司，开发有针对性的RNAi疗法，今天宣布，该公司将在以下即将发生的事件作演讲。
2015肝病会议上®，肝病研究的美国协会第六十六届年会（AASLD）-三藩，十一月13-17日，2015
十一月十五日，下午3:15 PST Christine wooddell，博士，箭头组组长将提供一个口头报告的题目是，“统”与慢性乙型肝炎病毒感染的黑猩猩ARC-520治疗下减少维持cccDNA牵连HBsAg循环“十一月十六日完整的DNA，上午8点-下午5:30 PST -文凤园，医学博士，博士，主席胃肠病学和肝病学，香港大学，和服务副总裁，玛丽女王医院医学系，香港，将提供一个最新海报演讲题为“生产，ARC-520患者的II期研究深层和持久抑制病毒抗原和DNA与慢性乙型肝炎
十一月十六日，6:30 p.m. PST -箭头管理将举办分析师和投资者接待洽谈ARC-520和关键数据在会议上
十一月十七日，上午8:00 - 12:00 PST Christine wooddell，博士，箭头组组长将海报演讲题为，“每月剂量的ARC-520在慢性乙型肝炎病毒感染的黑猩猩产生快速，深刻和持久的病毒抗原“杰夫里秋2015全球医疗保健会议-伦敦，英国，十一月18-19日循环减少，2015
十一月十九日，下午2:40 GMT -克里斯Anzalone箭头，博士，总裁和首席执行官，将呈现一个overviewpiper Jaffray公司第二十七年度医疗保健会议-纽约，十二月1-2日，2015
十二月二日，下午3:00 EST克里斯Anzalone，箭头博士，总裁兼首席执行官，将在一个TED使用炉边聊天目前公司概况，高级研究分析师，Piper jaffrayhep镖2015 -威雷亚，夏威夷，十二月6-10日，2015
十二月二日，40 HST -布鲁斯，医学博士，首席运营官的箭头，将提供一个口头报告的题目是，“对HBV生物学从ARC-520发展计划”十二月八日的新见解，4:00 - 5:30 HST Christine wooddell，博士，箭头组组长将海报演讲题为，“HBsAg持续减少，与核苷类似物联合治疗/ ARC-520慢性HBV感染的黑猩猩HBV DNA和HBeAg血清转换